TY - JOUR T1 - Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. AU - Giannotti,Federica, AU - Labopin,Myriam, AU - Shouval,Roni, AU - Sanz,Jaime, AU - Arcese,William, AU - Angelucci,Emanuele, AU - Sierra,Jorge, AU - Santasusana,Josep-Maria Ribera, AU - Santarone,Stella, AU - Benedetto,Bruno, AU - Rambaldi,Alessandro, AU - Saccardi,Riccardo, AU - Blaise,Didier, AU - Carella,Michele Angelo, AU - Rocha,Vanderson, AU - Baron,Frederic, AU - Mohty,Mohamad, AU - Ruggeri,Annalisa, AU - Nagler,Arnon, Y1 - 2018/08/30/ PY - 2018/07/15/received PY - 2018/08/22/accepted PY - 2018/9/1/entrez PY - 2018/9/1/pubmed PY - 2020/1/10/medline KW - Acute myeloid leukemia KW - Conditioning regimens KW - Haploidentical stem cell transplantation KW - Stem cell transplantation KW - Thiotepa-busulfan-fludarabine KW - Umbilical cord blood transplantation SP - 110 EP - 110 JF - Journal of hematology & oncology JO - J Hematol Oncol VL - 11 IS - 1 N2 - BACKGROUND: Thiotepa-busulfan-fludarabine (TBF) is a widely used conditioning regimen in single umbilical cord blood transplantation (SUCBT). More recently, it was introduced in the setting of non-T cell depleted haploidentical stem cell transplantation (NTD-Haplo). Whether TBF based conditioning provides additional benefit in transplantation from a particular alternative donor type remains to be established. METHODS: This was a retrospective study based on an international European registry. We compared outcomes of de-novo acute myeloid leukemia patients in complete remission receiving NTD-Haplo (n = 186) vs. SUCBT (n = 147) following myeloablative conditioning (MAC) with TBF. Median follow-up was 23 months. Treatment groups resembled in baseline characteristics. RESULTS: SUCBT was associated with delayed engraftment and higher graft failure. In multivariate analysis no statistically significant differences were observed between the two groups in terms of acute or chronic graft-versus-host disease (GvHD) (HR = 1.03, p = 0.92 or HR = 1.86, p = 0.21) and relapse incidence (HR = 0.8, p = 0.65). Non-relapse mortality (NRM) was significantly higher in SUCBT as compared to NTD-Haplo (HR = 2.63, p = 0.001); moreover, SUCBT did worse in terms of overall survival (HR = 2.18, p = 0.002), leukemia-free survival (HR = 1.94, p = 0.007), and GvHD relapse-free survival (HR = 2.38, p = 0.0002). CONCLUSIONS: Our results suggest that TBF-MAC might allow for a potent graft-versus-leukemia, regardless of the alternative donor type. Furthermore, in patients receiving TBF-MAC, survival with NTD-Haplo may be better compared to SUCBT due to decreased NRM. SN - 1756-8722 UR - https://www.unboundmedicine.com/medline/citation/30165887/Haploidentical_transplantation_is_associated_with_better_overall_survival_when_compared_to_single_cord_blood_transplantation:_an_EBMT_Eurocord_study_of_acute_leukemia_patients_conditioned_with_thiotepa_busulfan_and_fludarabine_ L2 - https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0655-8 DB - PRIME DP - Unbound Medicine ER -